Tango Therapeutics (TNGX) Operating Margin (2020 - 2025)
Tango Therapeutics (TNGX) recorded quarterly Operating Margin of 26.15% in Q3 2025, up 102.03% quarter-over-quarter from 1287.87% in Q2 2025, and up 30941.0% on a YoY basis from N/an in Q3 2024.
Tango Therapeutics (TNGX) Operating Margin (2020 - 2025) Analysis & Trends
Tango Therapeutics' Operating Margin history runs 6 years deep, the most recent figure standing at 26.15% for Q3 2025.
- In Q3 2025, Operating Margin rose 30941.0% year-over-year to 26.15%; the TTM figure through Mar 2026 stood at 48.38% (up 30748.0% YoY), while the FY2025 annual figure was 34.2%, up 31189.0% from the prior year.
- Operating Margin was 26.15% for Q3 2025 at Tango Therapeutics, up from 1287.87% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 26.15% in Q3 2025 to a low of 1287.87% in Q2 2025.
- Historically, Operating Margin has averaged 440.58% across 5 years, with a median of 432.41% in 2022.
- Biggest YoY gain for Operating Margin was 30941 bps in 2025; the steepest drop was 113918 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 384.6% in 2021, then slipped by 24 bps to 476.79% in 2022, then sank by 35 bps to 644.69% in 2023, then slumped by 54 bps to 993.68% in 2024, then soared by 103 bps to 26.15% in 2025.
- The last three Operating Margin figures came in at 26.15% (Q3 2025), 1287.87% (Q2 2025), and 788.76% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 26.15% |
| Jun 30, 2025 | -1,287.87% |
| Mar 31, 2025 | -788.76% |
| Dec 31, 2024 | -993.68% |
| Sep 30, 2024 | -283.26% |
| Jun 30, 2024 | -148.69% |
| Mar 31, 2024 | -652.99% |
| Dec 31, 2023 | -644.69% |
| Sep 30, 2023 | -238.78% |
| Jun 30, 2023 | -159.25% |
| Mar 31, 2023 | -525.25% |
| Dec 31, 2022 | -476.79% |
| Sep 30, 2022 | -432.41% |
| Jun 30, 2022 | -436.70% |
| Mar 31, 2022 | -440.76% |
| Dec 31, 2021 | -384.60% |
| Sep 30, 2021 | -288.33% |
| Jun 30, 2021 | -25.10% |
| Mar 31, 2021 | -189.18% |
| Dec 31, 2020 | -2.94% |